Peking University Third Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma

  NCT07901569· Liu Zhuo· Source

• Not yet recruiting

  Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults

  NCT07835152· Phase 3· Brise Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Chinese Multicenter Registry for Peutz-Jeghers Syndrome

  NCT07889596· First People's Hospital of Hangzhou· Source

• Recruiting

  Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA

  NCT07822711· Peking University Third Hospital· Source

• Not yet recruiting

  Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer

  NCT07882628· Beijing Chao Yang Hospital· Source

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Not yet recruiting

  A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).

  NCT07784101· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Not yet recruiting

  A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease

  NCT07848880· Phase 2· Zhejiang Doer Biologics Co., Ltd.· Source

• Recruiting

  Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults

  NCT07792681· Phase 2/3· Brise Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07871110· Phase 2· TransThera Sciences (Nanjing), Inc.· Source

• Recruiting

  A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

  NCT07787169· Phase 1· Eli Lilly and Company· Source

• Not yet recruiting

  A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer

  NCT07782086· Shuangyue Liu· Source

• Recruiting

  A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis

  NCT07724366· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  Acupuncture for Insulin Resistance in Women With Polycystic Ovary Syndrome

  NCT07806656· Peking University Third Hospital· Source

• Recruiting

  68Ga-SorB PET/CT Imaging in Patients With Solid Tumors

  NCT07760012· Peking University Third Hospital· Source

• Recruiting

  Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection Fraction

  NCT07693049· Peking University Third Hospital· Source

• Not yet recruiting

  The Effect of Ligament of Marshall Excision During Minimally Invasive Cardiac Surgery-Coronary Artery Bypass Grafting (MICS-CABG) on the Prevention of Postoperative New-Onset Atrial Fibrillation: A Multicenter, Prospective, Randomized, Triple-Blinded Study

  NCT07755072· Peking University Third Hospital· Source

• Not yet recruiting

  A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD

  NCT07658339· Phase 3· Haisco Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  Multimodal Ocular Diagnosis-Guided Precision Acupuncture and Lifestyle Intervention for PCOS

  NCT07809503· Peking University Third Hospital· Source

• Not yet recruiting

  Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOS

  NCT07687667· Peking University Third Hospital· Source

• Recruiting

  Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities

  NCT07781124· Vantive Health LLC· Source

• Recruiting

  Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer

  NCT07552402· Harbin Medical University· Source

• Not yet recruiting

  Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy

  NCT07627464· Phase 2· Tianjin Medical University Cancer Institute and Hospital· Source

• Recruiting

  A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  NCT07477587· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants

  NCT07559240· Phase 1· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens

  NCT07579936· Phase 2· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

  NCT07571161· Phase 3· Eli Lilly and Company· Source

• Recruiting

  NK Cell Therapy for Malignant Solid Brain Tumors

  NCT07552233· Peking University Third Hospital· Source

• Active, not recruiting

  IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

  NCT07473960· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Not yet recruiting

  A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy

  NCT07421284· Phase 3· CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.· Source

• Recruiting

  Radiotherapy After Prostatectomy for Node Positive Prostate Cancer

  NCT07477626· Phase 3· Sun Yat-sen University· Source

• Recruiting

  A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy

  NCT07777861· Phase 2· Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.· Source

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Takeda· Source

• Recruiting

  A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

  NCT07462780· Phase 1· Shenzhen Kangzhe Biotechnology Co., Ltd.· Source

• Recruiting

  A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia

  NCT07421297· Phase 3· CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

  NCT07276958· Phase 1· Eli Lilly and Company· Source

• Not yet recruiting

  NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC

  NCT07412171· Phase 2· Peking University Third Hospital· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

  NCT07347600· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

  NCT07321873· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases

  NCT07301164· Early phase 1· Peking University Third Hospital· Source

• Active, not recruiting

  A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

  NCT07223723· Phase 4· Biogen· Source

• Recruiting

  Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

  NCT07262645· Phase 3· Danyang Huichuang Medical Equipment Co., Ltd.· Source

• Recruiting

  A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo

  NCT07153666· Peking University Third Hospital· Source

• Recruiting

  A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

  NCT07250802· Phase 3· Takeda· Source

Showing 50 of 267.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer11 recruiting
• Obesity9 recruiting
• Mantle cell lymphoma8 recruiting
• Prostate cancer8 recruiting
• Multiple myeloma7 recruiting
• ALS (motor neurone disease)6 recruiting
• Alzheimer disease6 recruiting
• Chronic lymphocytic leukaemia6 recruiting
• Ovarian cancer6 recruiting
• Polycystic ovary syndrome6 recruiting
• Systemic sclerosis (scleroderma)6 recruiting
• Bladder cancer5 recruiting
• Crohn's disease5 recruiting
• Diffuse large B-cell lymphoma5 recruiting
• Heart failure5 recruiting
• Kidney cancer5 recruiting
• Psoriasis5 recruiting
• Rheumatoid arthritis5 recruiting
• Atopic dermatitis (eczema)4 recruiting
• Atrial fibrillation4 recruiting
• Childhood cancers4 recruiting
• Chronic kidney disease4 recruiting
• Gastric and oesophageal cancer4 recruiting
• Migraine4 recruiting
• Pancreatic cancer4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• ANCA-associated vasculitis3 recruiting
• Dermatomyositis and polymyositis (myositis)3 recruiting
• Liver and biliary tract cancer3 recruiting
• Lupus (SLE)3 recruiting
• Metastatic breast cancer3 recruiting
• Osteoporosis3 recruiting
• Sjögren's disease3 recruiting
• Type 2 diabetes3 recruiting
• Acute myeloid leukaemia2 recruiting
• Bronchiectasis2 recruiting
• Cervical cancer2 recruiting
• Colorectal cancer2 recruiting
• COPD2 recruiting
• Coronary artery disease2 recruiting
• Diabetic eye disease2 recruiting
• Familial hypercholesterolaemia2 recruiting
• Glioblastoma2 recruiting
• Graves' disease and hyperthyroidism2 recruiting
• High blood pressure2 recruiting
• Immune thrombocytopenia (ITP)2 recruiting
• Peripheral artery disease2 recruiting
• Retinitis pigmentosa2 recruiting
• Stroke2 recruiting
• Tuberculosis2 recruiting
• Vitiligo2 recruiting
• Asthma1 recruiting
• Fabry disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Fibromyalgia1 recruiting
• Follicular lymphoma1 recruiting
• Glaucoma1 recruiting
• Head and neck cancer1 recruiting
• Hepatitis B1 recruiting
• Hidradenitis suppurativa1 recruiting
• Macular degeneration1 recruiting
• Melanoma1 recruiting
• Meningioma1 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoarthritis1 recruiting
• Psoriatic arthritis1 recruiting
• Spinal muscular atrophy1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Terminated

  A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

  NCT07314060· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

  NCT07145229· Phase 2· Atom Therapeutics Co., Ltd· Source

• Completed

  A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight

  NCT07004322· Phase 1· Novo Nordisk A/S· Source

• Completed

  Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

  NCT06924385· Phase 1· Xiamen Amoytop Biotech Co., Ltd.· Source

• Completed

  The First-in-Human Study of GW906 Injection

  NCT07884461· Phase 1· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source

• Completed

  Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females

  NCT06893796· Phase 1· Xiamen Amoytop Biotech Co., Ltd.· Source

• Recruiting

  Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06842199· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Completed

  Robot-assisted Training

  NCT06648486· Peking University Third Hospital· Source

• Completed

  A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

  NCT07421232· Phase 2· CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.· Source

• Completed

  Prospective, Multicenter, Self-controlled Clinical Trial to Validate Optical Ultrasonic Flow Ratio (OUFR)

  NCT06726252· Harbin Medical University· Source

• Completed

  Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects

  NCT06501586· Phase 1· Suzhou Sanegene Bio Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06700499· Phase 2· Akeso· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

  NCT06342713· Phase 1· BeiGene· Source

• Completed

  Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)

  NCT06829225· Phase 1· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

  NCT06280716· Phase 3· Eli Lilly and Company· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Completed

  Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)

  NCT06230822· Phase 1· Wuhan Optics Valley Vcanbiopharma Co., Ltd.· Source

• Completed

  the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C

  NCT06132360· Phase 1· Shanghai Rona Therapeutics Co., Ltd.· Source

• Terminated

  A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT06035393· Phase 2· Jiangsu HengRui Medicine Co., Ltd.· Source

• Withdrawn

  Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

  NCT06176235· Phase 2· Peking University People's Hospital· Source

• Completed

  A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

  NCT06122649· Phase 3· Amgen· Source

• Completed

  An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

  NCT06116968· Phase 3· Corxel Pharmaceuticals· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06092762· Phase 2· Akeso· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source

• Completed

  The Accuracy of Ultrasonic Viscoelastic Imaging in Evaluating the Severity of Chronic Kidney Diseases

  NCT06961162· Peking University Third Hospital· Source

• Completed

  A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia

  NCT07295418· Phase 3· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source

• Terminated

  TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

  NCT06106841· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Completed

  A Randomized Controlled Trial of Acupuncture for Insulin Resistance in Patients With Polycystic Ovary Syndrome

  NCT06306417· Peking University Third Hospital· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

  NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Evaluating Different Doses of Orelabrutinib in MCL

  NCT05978739· Phase 2· InnoCare Pharma Inc.· Source

• Completed

  Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

  NCT05959083· AbbVie· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.

  NCT06147544· Phase 1/2· PegBio Co., Ltd.· Source

• Terminated

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· Phase 1· BeOne Medicines· Source

• Completed

  A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

  NCT05770609· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· Phase 3· AbbVie· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

  NCT05881837· Phase 2· Fujian Shengdi Pharmaceutical Co., Ltd.· Source

• Completed

  AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

  NCT07030595· Phase 3· Alebund Pharmaceuticals· Source

• Completed

  A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05507580· Phase 4· AbbVie· Source

• Completed

  A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects

  NCT06158737· Phase 1· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Evaluation of the Effect of Triamcinolone at Different Doses on LIA During TKA

  NCT05997238· Phase 4· Peking University Third Hospital· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

  NCT06066125· Phase 3· Akeso· Source

• Terminated

  A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

  NCT05709093· Phase 3· TJ Biopharma Co., Ltd.· Source

• Completed

  A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

  NCT05687032· Phase 4· Pfizer· Source

• Completed

  A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

  NCT05810948· Phase 2· argenx· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· The George Institute· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

Showing 50 of 104.

Conditions

Diseases this institution publishes on or runs trials for.

• Osteoarthritis69 works · 4 trials
• Polycystic ovary syndrome44 works · 10 trials
• COPD44 works · 4 trials
• Kidney cancer39 works · 6 trials
• Bladder cancer28 works · 11 trials
• ALS (motor neurone disease)26 works · 8 trials
• Osteoporosis23 works · 5 trials
• Diabetic eye disease21 works · 2 trials
• Cervical cancer21 works · 3 trials
• Spinal cord injury17 works · 2 trials
• Glaucoma16 works · 3 trials
• Obstructive sleep apnoea16 works · 1 trial
• Mantle cell lymphoma11 works · 14 trials
• Follicular lymphoma5 works · 10 trials
• Sjögren's disease4 works · 4 trials
• Charcot-Marie-Tooth disease4 works · 1 trial
• Aplastic anaemia3 works · 0 trials